Role of infections in atherogenesis

Indian Heart Journal

Volumn 55, Issue 1, 2003, Pages 27-34

  Laroia, Sandeep T ^a   Ganti, Apar Kishor ^a   Potti, Anil ^a  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROXITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANTIBODY TITER; ATHEROGENESIS; ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FOLLOW UP; HELICOBACTER PYLORI; HERPES VIRUS; HUMAN; INFECTION; MECHANICAL STRESS; MONOCYTE; NONHUMAN; PATHOGENESIS; REVIEW; SMOOTH MUSCLE; SURVIVAL; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; CYTOMEGALOVIRUS INFECTIONS; ENDOTHELIUM, VASCULAR; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HERPESVIRIDAE INFECTIONS; HUMANS;

EID: 0037617666     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Ophuls W. Arteriosclerosis and cardiovascular disease. JAMA 1921; 76: 700-701
2. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-340
3. Lorber B. Are all diseases infectious? Another look. Ann Intern Med 1999; 131: 989-990
4. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-436
5. Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation 1998; 97: 1671-1674
6. Fuster V. Human lesion studies. In: Numano F, Ross R (eds). Atherosclerosis IV: recent advances in atherosclerosis research, New York City: The New York Academy of Sciences; 1997. pp. 207-225
7. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis 1997; 39: 287-324
8. Fuster V. Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992; 326: 242-250
9. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989: 9: (Suppl) I19-I32
10. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 1994; 266: H2535-H2541
11. Bhagat K, Moss R, Collier J, Vallance P. Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction? Cardiovasc Res 1996; 32: 822-829
12. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ. Herpes simplex virus infection in human arterial cells. Implications in arteriosclerosis. J Clin Invest 1987; 80: 1317-1321
13. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994: 265: 391-394
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
15. Woodhouse PR, Khaw KT, Plummer M, Foley A, Meade TW. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 435-439
16. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566
17. Zhu J, Shearer GM, Norman JE, Pinto LA, Marincola FM, Prasad A, et al. Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease: sex-based differences in inflammation and type of immune response. Circulation 2000; 102: 2491-2496
18. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 2000; 102: 1917-1923
19. Siscovick DS. Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000; 102: 2335-2340
20. Horvath R, Cerny J, Benedik J Jr, Hokl J, Jelinkova I, Benedik J. The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol 2000; 16: 17-24
21. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2000; 160: 2027-2032
22. Kaftan HA, Kaftan O, Kilic M. Markers of chronic infection and inflammation. Are they important in cases with chronic coronary heart disease. Jpn Heart J 1999; 40: 275-280
23. Neumann FJ. Kastrati A, Miethke T, Pogatsa-Murray G, Seyfarth M, Schomig A. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. Circulation 2000; 101: 11-13
24. Biocina B, Husedzinovic I, Sutlic Z. Presecki V, Wallwork J. Cytomegalovirus disease as a possible etiologic factor for early atherosclerosis. Coll Antropol 1999; 23: 673-681
25. Blum A, Giladi M, Weinberg M, Kaplan G, Pasternack H. Laniado S, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998; 81: 866-868
26. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu Zx, Finkel T, et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-630
27. Alber DG, Powell KL, Vallance P, Goodwin DA, Grahame-Clarke C. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 2000: 102: 779-785
28. Lemstrom K, Sihvola R, Bruggeman C, Hayry P, Koskinen P. Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 1997; 95: 2614-2616
29. Zhou YF, Shou M, Guetta E, Guzman R, Unger EF, Yu ZX, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999: 100: 1569-1575
30. Lin TM, Jiang MJ, Eng HL, Shi GY, Lai LC, Huang BJ, et al. Experimental infection with bovine herpesvirus-4 enhances atherosclerotic process in rabbits. Lab Invest 2000: 80: 3-11
31. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D. et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-439
32. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-714
33. Gunn M, Stephens JC, Thompson JR, Rathbone BJ, Samani NJ. Significant association of cagA positive Helicobacter pylori strains with risk of premature myocardial infarction. Heart 2000; 84: 267-271
34. Kahan T, Lundman P, Olsson G, Wendt M. Greater than normal prevalence of seropositivity for Helicobacter pylori among patients who have suffered myocardial infarction. Coron Artery Dis 2000; 11: 523-526
35. Farsak B. Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, et al, Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38; 4408-4411
36. Hoffmeister A, Rothenbacher D, Bode G. Persson K, Marz W, Nauck MA, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol 2001; 21: 427-432
37. Pieniazek P, Karczewska E, Duda A, Tracz W, Pasowicz M, Konturek SJ. Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol 1999; 50: 743-751
38. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques, Stroke 2001; 32: 385-391
39. Laurila A, Bloigu A. Nayha S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis 1999; 142: 207-210
40. Markus HS, Mendall MA. Helicobacterpylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry 1998; 64: 104-107
41. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-394
42. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-753
43. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model, Circulation 1998; 97; 633-636
44. Liu L, Hu H, Ji H, Murdin AD, Pierce GN, Zhong G. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR -/- mouse model within six months. Mol Cell Biochem 2000; 215: 123-128
45. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayson JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993: 167: 841-849
46. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-1561
47. Ericson K, Saldeen TG, Lindquist O, Pahlson C, Mehta JL. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000; 101: 2568-2571
48. Maass M, Bartels C, Kruger S, Krause E, Engel PM, Dalhoff K. Endovascular presence of Chlamydia pneumoniae DNA is a generalized phenomenon in atherosclerotic vascular disease. Atherosclerosis 1998; 140 (Suppl): S25-S30
49. Bartels C, Maass M, Bein G, Malisius R, Brill N, Bechtel JF, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99: 879-882
50. Ouchi K, Fujii B, Kudo S, Shirai M, Yamashita K, Gondo T, et al. Chlamydia pneumoniae in atherosclerotic and nonatherosclerotic tissue. J Infect Dis 2000; 181 (Suppl): S441-S443
51. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-986
52. Gabriel AS, Gnarpe H, Gnarpe J, Hallander H, Nyquist O, Martinsson A. The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischaemic heart disease. Eur Heart J 1998; 19: 1321-1327
53. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998; 19: 570-577
54. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993; 95: 499-504
55. Burian K, Kis Z, Virok D, Endresz V, Prohaszka Z, Duba J. et al. Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis. Circulation 2001; 103: 1503-1508
56. Leowattana W, Mahanonda N, Bhuripanyo K, Pokium S, Kiartivich S, Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in Thailand. J Med Assoc Thai 2000; 83: 1054-1058
57. Maass M, Jahn J, Gieffers J, Dalhoff K, Katus HA, Solbach W. Detection of Chlamydia pneumoniae within peripheral blood monocytes of patients with unstable angina or myocardial infarction. J Infect Dis 2000: 181 (Suppl): S449-S451
58. Kaftan AH, Kaftan O. Coronary artery disease and infection with chlamydia pneumonia. Jpn Heart J 2000; 41: 165-172
59. Sessa R, Di Pietro M, Santino I, del Piano M, Varveri A, Dagianti A, et al. Chlamydia pneumoniae infection and atherosclerotic coronary disease. Am Heart J 1999; 137: 1116-1119
60. Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435-1439
61. Dechend R, Maass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100: 1369-1373
62. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae induced atherosclerosis. J Infect Dis 2000; 181 (Suppl): S514-S518
63. Choussat R, Montalescot G, Collet J, Jardel C, Ankri A, Fillet A, et al. Effect of prior exposure to Chlamydia pneumoniae. Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. Am J Cardiol 2000; 86: 379-384
64. Adler SP, Hur JK, Wang JB, Vetrovec GW. Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998; 177: 209-212
65. Niemela S, Karttunen T, Korhonen T, Laara E, Karttunen R, Ikaheimo M, et al, Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996; 75: 573-575
66. Tsai CJ. Huang TY. Relation of Helicobacter pylori infection and angiographically demonstrated coronary artery disease. Dig Dis Sci 2000; 45: 1227-1232
67. Menge H, Lang A, Brosius B, Hopert R, Lollgen H. Helicobacter pylori and coronary heart diseases - hypotheses and facts. Z Gastroenterol 2000; 38: 315-323
68. Quinn MJ, Foley JB, Mulvihill NT, Lee J, Crean PA, Walsh MJ. et al. Helicobacter pylori serology in patients with angiographically documented coronary artery disease. Am J Cardiol 1999; 83: 1664-1666
69. Basili S, Vieri M, Di Lecce VN, Maccioni D, Marmifero M, Paradiso M, et al. Association between histological diagnosis of Helicobacter pylori and coronary heart disease: results of a retrospective study. Clin Ter 1998; 149: 413-417
70. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ 1998; 316: 1130-1132
71. Khurshid A, Fenske T, Bajwa T, Bourgeois K, Vakil N. A prospective, controlled study of Helicobacter pylori seroprevalence in coronary artery disease. Am J Gastroenterol 1998; 93: 717-720
72. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-1164
73. Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H. Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999; 100: 832-837
74. Hoffmeister A, Rothenbacher D, Wanner P, Bode G, Persson K, Brenner H, et al. Seropositivity to chlamydial lipopolysaccharide and Chlamydia pneumoniae, systemic inflammation and stable coronary artery disease: negative results of a case-control study. J Am Coll Cardiol 2000; 35: 112-128
75. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P. et al. Chlamydia pneumoniae IgG titers and coronary heart disease: prospective study and meta-analysis. BMJ 2000: 321: 208-213
76. Romeo F, Martuscelli E, Chirieolo G, Cerabino LM, Ericson K, Saldeen TG, et al. Seropositivity against Chlamydia pneumoniae in patients with coronary atherosclerosis. Clin Cardiol 2000: 23: 327-330
77. Cellesi C, Sansoni A, Casini S, Migliorini L, Zacchini F, Gasparini R, et al, Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy. Atherosclerosis 1999; 145: 81-85
78. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-238
79. Aalto-Setala K, Laitinen K, Erkkila L, Leinonen M, Jauhiainen M, Ehnholm C. et al. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 578-584
80. Blessing E, Lin TM, Campbell LA, Rosenfeld ME, Lloyd D, Kuo C. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. Infect Immun 2000; 68: 4765-4768
81. Haberbosch W, Jantos C. Chlamydia pneumoniae infection is not an independent risk factor for arterial disease. Herz 2000; 25: 79-83
82. Anderson JL, Muhlestein JB. Carlquist J, Allen A, Trehan S, Nielson C. et al. Randomized secondary prevention trial with azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-1547
83. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105: 1298-1303
84. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407
85. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-407
86. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20: 121-127
87. Cercek B. Azithromycin in Acute Coronary Syndrome Investigators. The effect of short-term treatment with azithromycin on recurrent ischemic events in patients with acute coronary syndrome. Program and abstracts of the American College of Cardiology 51st Annual Meeting; 2002 March 17-20: Atlanta, Georgia. [Abstr] p. 503
88. Dunne M, O'Connor C, Pfeffer M, Muhlestein B, Gupta S, Yao L. Weekly Intervention with Zithromax for Atherosclerosis and Its Related Disorders (The WIZARD Study). Program and abstracts of the American College of Cardiology 51st Annual Meeting; 2002. March 17-20; Atlanta, Georgia [Abstr] p, 504